An2 therapeutics director Robin Readnour sells $6,674 in shares By Investing.com

Robin Shane Readnour, a director at AN2 Therapeutics, Inc. (), sold shares totaling $6,674 on September 9, 2026. The sales occurred at prices ranging from $6.02 to $6.04 per share. The timing is notable as the stock has declined 8.2% over the past week to $5.41, though shares remain up 323% over the past year. According to InvestingPro analysis, ANTX appears overvalued at current levels, with the stock trading above its Fair Value. Investors can access detailed valuation metrics and 6 additional ProTips on the most overvalued stocks list.

The transactions involved two separate dispositions of common stock. MGC Venture Partners 2018, LP sold 523 shares for a total of $3,150, while MGC Venture Partners QP 2018, LP disposed of 585 shares, valued at $3,524. Both sales were executed automatically pursuant to Rule 10b5-1 trading plans, which were adopted on April 23, 2026.

Mr. Readnour is a member of the Issuer’s board of directors and a managing partner of MGC Venture Partners 2018 GP, LLC, which serves as the general partner for both MGC 2018 LP and MGC 2018 QP. Mr. Readnour possesses shared voting and dispositive power over the shares held by these entities but disclaims beneficial ownership of the securities, except to the extent of their pecuniary interest.

Following these transactions, MGC Venture Partners 2018, LP indirectly holds 557,467 shares, and MGC Venture Partners QP 2018, LP indirectly holds 624,765 shares.

In other recent news, Guggenheim has initiated coverage on AN2 Therapeutics with a buy rating, setting a price target of $9.00. This development highlights the potential of AN2 Therapeutics’ drug, epetraborole, which could become the first oral medication for managing hematocrit levels in patients with polycythemia vera. Currently, hematocrit control is achieved through frequent phlebotomies and cytoreductive therapies, which can be toxic. The introduction of an oral alternative could significantly impact treatment protocols. Guggenheim’s initiation of a buy rating underscores the firm’s positive outlook on the company’s potential in this area. These recent developments are significant for investors monitoring AN2 Therapeutics’ progress and future prospects in the medical field.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.